These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11782896)

  • 1. Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats.
    Jauregizar N; Calvo R; Suarez E; Quintana A; Raczka E; Lukas JC
    J Pharm Sci; 2002 Jan; 91(1):41-52. PubMed ID: 11782896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered disposition and effect of lerisetron in rats with elevated alpha 1-acid glycoprotein levels.
    Jauregizar N; Calvo R; Suarez E; Quintana A; Raczka E; Lukas JC
    Pharm Res; 2001 Jun; 18(6):838-45. PubMed ID: 11474789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: a population pharmacokinetic model.
    Jauregizar N; Quintana A; Suarez E; Raczka E; de la Fuente L; Calvo R
    Gerontology; 2003; 49(4):205-14. PubMed ID: 12792155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model.
    Ortega F; Quintana A; Suárez E; Lukas JC; Jauregizar N; de la Fuente L; Lucero ML; Gonzalo A; Orjales A; Calvo R
    Pharm Res; 2005 Nov; 22(11):1769-82. PubMed ID: 16158214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer.
    Calvo R; Jiménez RM; Trocóniz IF; Suárez E; Gonzalo A; Lucero ML; Raczka E; Orjales A
    Cancer Chemother Pharmacol; 1998; 42(5):418-22. PubMed ID: 9771958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
    Cooper M; Sologuren A; Valiente R; Smith J
    Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lerisetron. F 0930, F 0930RS.
    Drugs R D; 1999 Oct; 2(4):245-6. PubMed ID: 10659400
    [No Abstract]   [Full Text] [Related]  

  • 8. 5-HT(3)R binding of lerisetron: an interdisciplinary approach to drug-Receptor interactions.
    Parihar HS; Suryanarayanan A; Ma C; Joshi P; Venkataraman P; Schulte MK; Kirschbaum KS
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2133-6. PubMed ID: 11514154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
    Orjales A; Mosquera R; Labeaga L; Rodes R
    J Med Chem; 1997 Feb; 40(4):586-93. PubMed ID: 9046349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species difference in the 5-hydroxytryptamine3 receptor associated with the von Bezold-Jarisch reflex.
    Yamano M; Ito H; Kamato T; Miyata K
    Arch Int Pharmacodyn Ther; 1995; 330(2):177-89. PubMed ID: 8861711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New benzimidazole derivatives: selective and orally active 5-HT3 receptor antagonists.
    Pascual D; Girón R; Alsasua A; Benhamú B; López-Rodríguez ML; Martín MI
    Eur J Pharmacol; 2003 Feb; 462(1-3):99-107. PubMed ID: 12591101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog.
    Gomez-de-Segura IA; Grande AG; De Miguel E
    Acta Oncol; 1998; 37(7-8):759-63. PubMed ID: 10050999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of 5-HT3 receptors in the NTS inhibits the cardiac Bezold-Jarisch reflex response.
    Sévoz C; Nosjean A; Callera JC; Machado B; Hamon M; Laguzzi R
    Am J Physiol; 1996 Jul; 271(1 Pt 2):H80-7. PubMed ID: 8760161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the bradycardic component of the von Bezold-Jarisch reflex and carotid chemoreceptor reflex by periaqueductal gray stimulation: involvement of medullary receptors.
    Netzer F; Mandjee N; Verberne AJ; Bernard JF; Hamon M; Laguzzi R; Sévoz-Couche C
    Eur J Neurosci; 2009 May; 29(10):2017-28. PubMed ID: 19453625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional group interactions of a 5-HT3R antagonist.
    Venkataraman P; Joshi P; Venkatachalan SP; Muthalagi M; Parihar HS; Kirschbaum KS; Schulte MK
    BMC Biochem; 2002 Jun; 3():16. PubMed ID: 12079499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex.
    Godlewski G; Göthert M; Malinowska B
    Br J Pharmacol; 2003 Mar; 138(5):767-74. PubMed ID: 12642377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of serotonin3 receptors in the nucleus tractus solitarii on the carotid chemoreflex.
    Sévoz C; Callera JC; Machado BH; Hamon M; Laguzzi R
    Am J Physiol; 1997 Mar; 272(3 Pt 2):H1250-9. PubMed ID: 9087599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RS 23597-190: a potent and selective 5-HT4 receptor antagonist.
    Eglen RM; Bley K; Bonhaus DW; Clark RD; Hegde SS; Johnson LG; Leung E; Wong EH
    Br J Pharmacol; 1993 Sep; 110(1):119-26. PubMed ID: 8220871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that 5-HT3 receptors in the nucleus tractus solitarius and other brainstem areas modulate the vagal bradycardia evoked by activation of the von Bezold-Jarisch reflex in the anesthetized rat.
    Pires JG; Silva SR; Ramage AG; Futuro-Neto HA
    Brain Res; 1998 Apr; 791(1-2):229-34. PubMed ID: 9593908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.
    Leurs R; Tulp MT; Menge WM; Adolfs MJ; Zuiderveld OP; Timmerman H
    Br J Pharmacol; 1995 Oct; 116(4):2315-21. PubMed ID: 8564266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.